| Literature DB >> 22619494 |
Maciej Cedzynski1, Anna St Swierzko, David C Kilpatrick.
Abstract
This paper summarizes the data concerning soluble defense lectins (mannan-binding lectin, M-ficolin, L-ficolin, and H-ficolin) with the unique ability to activate complement and their associated serine proteases (MASPs) in neonates. The clinical importance of deficiencies of these immune factors is presented in aspects of perinatal mortality, premature births, and low birthweight. Prenatal serum concentrations of L-ficolin, H-ficolin, and MASP-2 (and probably M-ficolin) correlate with gestational age and birthweight. The relationship of serum MBL to gestational age is controversial. The MBL2 genotypes XA/O and O/O (associated with low-serum MBL) are associated with perinatal infections, whereas the high serum MBL-conferring A/A genotypes may be associated with prematurity. Low-serum L-ficolin concentrations, but not low-serum H-ficolin concentrations, are also associated with perinatal infections. Much of the literature is inconsistent, and the relationships reported so far require independent confirmation at both gene and protein levels. Our preliminary conclusion is that these soluble defense lectins play a protective role in the neonate, and that insufficiency of such factors contributes to the adverse consequences of prematurity and low birthweight.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22619494 PMCID: PMC3348535 DOI: 10.1155/2012/363246
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Figure 1The three major pathways of complement activation. These pathways differ crucially in their initiating events: the classical pathway depends on antibody recognition and binding to C1q; the alternative pathway depends on low-level spontaneous hydrolysis of C3 being stabilised by bacterial polysaccharides and so forth; and the lectin pathway depends on the recognition of saccharides by ficolins and certain collectins (MBL, CL-11). The common end result is the generation of C3a and C3b from C3; the classical and lectin pathways produce C4b2a as the C3 convertase, whereas that role is played by C3bBb in the alternative pathway. C1 inhibitor (C1inh) and C4-binding protein (C4bp) are downregulators of both classical and lectin pathways; H factor is an inhibitor of the early phase of alternative pathway, modified from [11].
Average (median, mean) concentrations or activities of selected complement lectin pathway factors (based on own investigation).
| Concentration/activity | References | |||
|---|---|---|---|---|
| Median | Mean | Range | ||
| MBL (ng/mL) | 1124 | 1213 | 0–5895 | [ |
| MASP-2 (ng/mL) | 93 | 118 | 0–812 | [ |
| MBL-MASP-2 (LP) (mU/mL) | 272 | 366 | 0–4112 | [ |
| L-ficolin (ng/mL) | 2500 | 2540 | 100–5700 | [ |
| H-ficolin (ng/mL) | 14600 | 15300 | 0–56500 | [ |
Some clinical associations of selected complement lectin pathway factors, based on own investigation.
| LP factor | Parameter | Clinical associations | Reference | ||
|---|---|---|---|---|---|
| Perinatal infections | Preterm/premature births1 | Low birth weight2 | |||
| MBL | Low cord serum concentration (<150 ng/mL) | no | no | no | [ |
| Genotype (promoter & exon 1) | XA/O and O/O | A/A (prematurity) | no | ||
| MASP-2 | Low cord serum concentration (<42 ng/mL) | no | yes | yes | [ |
| Genotype (D120G dimorphism) | no | no | no | ||
| MBL-MASP-2 complex activity | Low cord serum activity (<60 mU/mL) | no | yes | no | [ |
| L-ficolin | Low cord serum concentrations (<1 | yes | yes | yes | [ |
| H-ficolin | Low cord serum concentrations (<8.6 | no | yes | yes | [ |
| Genotype ( | no | no | no | ||
1Preterm births: gestational age ≤ 37 weeks; premature births: gestational age ≤ 35 weeks.
2Low birthweight: <2500 g.